Avoro Capital Advisors LLC Iovance Biotherapeutics, Inc. Transaction History

Avoro Capital Advisors LLC

$6.65 Billion
Q3 2024

A detailed history of Avoro Capital Advisors LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 4,240,000 shares of IOVA stock, worth $31.2 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

4,240,000

Previous 11,700,000 63.76%

Holding current value

$31.2 Million

Previous $93.8 Million 57.57%

% of portfolio

0.6%

Previous 1.28%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.28 - $11.9 $54.3 Million - $88.8 Million	-7,460,000 Reduced 63.76%	4,240,000 $39.8 Million
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $38 Million - $87.4 Million	5,000,000 Added 74.63%	11,700,000 $173 Million
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $1.72 Million - $2.9 Million	-320,000 Reduced 4.56%	6,700,000 $47.2 Million
Q4 2022 Feb 14, 2023	SELL	$5.62 - $10.0 $11.2 Million - $20 Million	-2,000,000 Reduced 22.17%	7,020,000 $44.9 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $1.91 Million - $2.62 Million	-200,000 Reduced 2.17%	9,020,000 $86.4 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $606,100 - $1.74 Million	95,000 Added 1.04%	9,220,000 $102 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $5.57 Million - $8.6 Million	450,000 Added 5.19%	9,125,000 $152 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $2.9 Million - $4.84 Million	175,000 Added 2.06%	8,675,000 $166 Million
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $12.2 Million - $16 Million	-600,000 Reduced 6.59%	8,500,000 $210 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $18 Million - $36.4 Million	1,100,000 Added 13.75%	9,100,000 $237 Million
Q1 2021 May 17, 2021	BUY	$28.67 - $52.59 $14.3 Million - $26.3 Million	500,000 Added 6.67%	8,000,000 $253 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $57.1 Million - $102 Million	-2,036,039 Reduced 21.35%	7,500,000 $348 Million
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $22.9 Million - $29.9 Million	-825,000 Reduced 7.96%	9,536,039 $314 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $36.8 Million - $55.4 Million	1,350,626 Added 14.99%	10,361,039 $284 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $3.6 Million - $7.16 Million	184,374 Added 2.09%	9,010,413 $270 Million
Q4 2019 Feb 14, 2020	SELL	$17.95 - $29.41 $31.9 Million - $52.2 Million	-1,775,000 Reduced 16.74%	8,826,039 $244 Million
Q3 2019 Nov 14, 2019	SELL	$17.99 - $26.0 $2.73 Million - $3.94 Million	-151,546 Reduced 1.41%	10,601,039 $193 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $2.17 Million - $5.44 Million	221,723 Added 2.11%	10,752,585 $264 Million
Q1 2019 May 15, 2019	BUY	$8.41 - $11.26 $2.27 Million - $3.04 Million	269,823 Added 2.63%	10,530,862 $100 Million
Q4 2018 Feb 14, 2019	BUY	$7.51 - $11.93 $12 Million - $19.1 Million	1,598,319 Added 18.45%	10,261,039 $90.8 Million
Q3 2018 Nov 14, 2018	BUY	$11.25 - $17.7 $5.46 Million - $8.58 Million	485,000 Added 5.93%	8,662,720 $97.5 Million
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $1.24 Million - $1.68 Million	99,215 Added 1.23%	8,177,720 $105 Million
Q1 2018 May 15, 2018	BUY	$8.1 - $19.5 $22.9 Million - $55.1 Million	2,825,055 Added 53.78%	8,078,505 $137 Million
Q4 2017 Feb 14, 2018	BUY	$6.65 - $9.25 $7 Million - $9.73 Million	1,052,107 Added 25.04%	5,253,450 $42 Million
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $18.7 Million - $35.9 Million	4,201,343	4,201,343 $32.6 Million

Others Institutions Holding IOVA

# of Institutions

313

Shares Held

237M

Call Options Held

3.77M

Put Options Held

1.7M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.16B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.

Account

Avoro Capital Advisors LLC Iovance Biotherapeutics, Inc. Transaction History